EA201171010A1 - Derivatives of 6- (6-O-Cycloalkyl- or 6-NH-Cycloalkyltriazolephenyl) Benzenothiazols and Benzimidazols: A METHOD OF OBTAINING, APPLICATION IN THE QUALITY OF DRUGS CORRECTIVE CORRELS CORRELS CORRELS CORRELING CORRELS CORRELING CORRELE-CORRECTIONS - Google Patents

Derivatives of 6- (6-O-Cycloalkyl- or 6-NH-Cycloalkyltriazolephenyl) Benzenothiazols and Benzimidazols: A METHOD OF OBTAINING, APPLICATION IN THE QUALITY OF DRUGS CORRECTIVE CORRELS CORRELS CORRELS CORRELING CORRELS CORRELING CORRELE-CORRECTIONS

Info

Publication number
EA201171010A1
EA201171010A1 EA201171010A EA201171010A EA201171010A1 EA 201171010 A1 EA201171010 A1 EA 201171010A1 EA 201171010 A EA201171010 A EA 201171010A EA 201171010 A EA201171010 A EA 201171010A EA 201171010 A1 EA201171010 A1 EA 201171010A1
Authority
EA
Eurasian Patent Office
Prior art keywords
correls
correling
cycloalkyl
cycloalkyltriazolephenyl
correle
Prior art date
Application number
EA201171010A
Other languages
Russian (ru)
Inventor
Эрик Бак
Консепсьон Немесек
Антонио Юголини
Сильви Венслер
Батист Ронан
Доминик Дамур
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи filed Critical Санофи
Publication of EA201171010A1 publication Critical patent/EA201171010A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Изобретение относится к новым соединениям формулы (I), в которойозначает простую или двойную связь; Ra означает -O-циклоалкил или -NH-циклоалкил; Х означает S, SO или SO; А означает NH или S; W означает Н, алкил или COR, где R означает циклоалкил; алкил; алкокси; O-фенил; -O-(CH)-фенил, где n=1-4; или NR1R2, где R1 означает Н или алкил и R2 означает Н, циклоалкил, гетероциклоалкил или алкил; или R1, R2 образуют вместе с N цикл, необязательно содержащий О, S, N и/или NH; причем все эти радикалы необязательно замещены; эти соединения, находящиеся во всех изомерных формах и в виде солей, используются в качестве лекарственных средств, в частности в качестве ингибиторов MET.The invention relates to new compounds of formula (I), in which means a single or double bond; Ra is —O-cycloalkyl or —NH-cycloalkyl; X is S, SO or SO; A is NH or S; W is H, alkyl or COR, where R is cycloalkyl; alkyl; alkoxy; O-phenyl; -O- (CH) -phenyl, where n = 1-4; or NR1R2, where R1 is H or alkyl and R2 is H, cycloalkyl, heterocycloalkyl or alkyl; or R1, R2 form together with N a ring optionally containing O, S, N and / or NH; moreover, all of these radicals are optionally substituted; these compounds, found in all isomeric forms and in the form of salts, are used as medicines, in particular as MET inhibitors.

EA201171010A 2009-02-06 2010-02-04 Derivatives of 6- (6-O-Cycloalkyl- or 6-NH-Cycloalkyltriazolephenyl) Benzenothiazols and Benzimidazols: A METHOD OF OBTAINING, APPLICATION IN THE QUALITY OF DRUGS CORRECTIVE CORRELS CORRELS CORRELS CORRELING CORRELS CORRELING CORRELE-CORRECTIONS EA201171010A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0900510A FR2941949B1 (en) 2009-02-06 2009-02-06 DERIVATIVES OF 6- (6-O-CYCLOALKYL OR 6-NH-CYCLOALKYL-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS INHIBITORS OF MET.
PCT/FR2010/050177 WO2010089506A1 (en) 2009-02-06 2010-02-04 Derivatives of 6-(6-o-cycloalkyl or 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors

Publications (1)

Publication Number Publication Date
EA201171010A1 true EA201171010A1 (en) 2012-03-30

Family

ID=40863635

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171010A EA201171010A1 (en) 2009-02-06 2010-02-04 Derivatives of 6- (6-O-Cycloalkyl- or 6-NH-Cycloalkyltriazolephenyl) Benzenothiazols and Benzimidazols: A METHOD OF OBTAINING, APPLICATION IN THE QUALITY OF DRUGS CORRECTIVE CORRELS CORRELS CORRELS CORRELING CORRELS CORRELING CORRELE-CORRECTIONS

Country Status (18)

Country Link
EP (1) EP2393790A1 (en)
JP (1) JP2012517407A (en)
KR (1) KR20110126660A (en)
CN (1) CN102388029A (en)
AR (1) AR075248A1 (en)
AU (1) AU2010212231A1 (en)
BR (1) BRPI1011354A2 (en)
CA (1) CA2751525A1 (en)
CO (1) CO6400222A2 (en)
EA (1) EA201171010A1 (en)
FR (1) FR2941949B1 (en)
IL (1) IL214407A0 (en)
MA (1) MA33102B1 (en)
MX (1) MX2011008312A (en)
SG (1) SG173558A1 (en)
TW (1) TW201040187A (en)
UY (1) UY32419A (en)
WO (1) WO2010089506A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
ZA200804681B (en) * 2005-11-30 2009-11-25 Vertex Pharma Inc Inhibitors of C-Met and uses thereof
EP1963329B1 (en) * 2005-11-30 2013-01-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
ME02736B (en) * 2005-12-21 2017-10-20 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
EP2032578A2 (en) * 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20121506A1 (en) * 2006-07-14 2012-11-26 Amgen Inc TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS
CA2667428A1 (en) * 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
PA8792501A1 (en) * 2007-08-09 2009-04-23 Sanofi Aventis NEW DERIVATIVES OF 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL AND BENCIMIDAZOL, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICATIONS, PHARMACEUTICAL COMPOSITIONS AND NEW MAIN USE AS MET INHIBITORS.

Also Published As

Publication number Publication date
BRPI1011354A2 (en) 2019-09-24
AR075248A1 (en) 2011-03-16
KR20110126660A (en) 2011-11-23
CN102388029A (en) 2012-03-21
SG173558A1 (en) 2011-09-29
MX2011008312A (en) 2011-11-02
EP2393790A1 (en) 2011-12-14
JP2012517407A (en) 2012-08-02
FR2941949A1 (en) 2010-08-13
CO6400222A2 (en) 2012-03-15
CA2751525A1 (en) 2010-08-12
IL214407A0 (en) 2011-09-27
AU2010212231A1 (en) 2011-08-25
WO2010089506A1 (en) 2010-08-12
FR2941949B1 (en) 2011-04-01
TW201040187A (en) 2010-11-16
UY32419A (en) 2010-09-30
MA33102B1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
CY1116987T1 (en) Concentrated imidazolylimidazoles as antiviral compounds
EA201301209A1 (en) PYRROLOTRIAZINON DERIVATIVES AS P13K INHIBITORS
EA201200938A1 (en) IMIDAZOPIRIDINE DERIVATIVES AS JAK INHIBITORS
EA201201677A1 (en) DERIVATIVES OF HETEROARILIMIDAZOLONE AS JAK INHIBITORS
EA201490474A1 (en) AMINOHINAZOLINS AS KINAZ INHIBITORS
EA201001013A1 (en) BIS (SULFONILAMINO) DERIVATIVES FOR USE IN THERAPY
EA201300250A1 (en) OXADIAZOL INHIBITORS OF LEUKOTRIEN PRODUCTION
EA201491824A1 (en) DERIVATIVES OF BENZAMIDE FOR INHIBITION OF ABL1, ABL2 AND BCR-ABL1 ACTIVITY
EA201200741A1 (en) METHOD OF OBTAINING DAGIGATRAN ETEXILATE
IN2014MN02106A (en)
UA117800C2 (en) URACYL OR TIMIN DERIVATIVES FOR TREATMENT OF HEPATITIS C
EA201101026A1 (en) BETA SECRETASE INHIBITORS
EA201490596A1 (en) NEW DYHYDROCHINOLIN-2-IT DERIVATIVES
EA201301319A1 (en) PYRIDIN-2 (1H) -ON DERIVATIVES, USED AS MEDICINES FOR THE TREATMENT OF MYELOPROLIFERATIVE DISTURBANCES, TRANSPLANT DISORDERS, IMMUNOLOGICALLY-CURRENT AND HEAT-DRIVERS
EA201491362A1 (en) ANESTHYZING COMPOUNDS AND METHODS OF THEIR APPLICATION
EA201291409A1 (en) DERIVATIVES OF INDOLYSINE, METHOD OF THEIR PRODUCTION AND THEIR THERAPEUTIC APPLICATION
EA200801608A1 (en) DERIVATIVES OF BENZIMIDAZOLONIC CARBONIC ACID
EA201490471A1 (en) PYRIDAZINOUS COMPOUNDS AND THEIR APPLICATION AS DAAO INHIBITORS
EA201492170A1 (en) NEW CYPRIDE N-PYRIDINYLAMIDES SUBSTITUTED AS A KINAZ INHIBITOR
EA201500298A1 (en) ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES
EA201490567A1 (en) NEW BICYCLIC DERIVATIVES OF DIHYDROCHINOLIN-2-IT
IN2014MN01521A (en)
EA201500182A1 (en) 4-METHYL-2,3,5,9,9b-PENTAASACYCLOPENT [a] NAFTAIL
EA201190293A1 (en) TRIPOLIDA SPIRITS
AR082968A1 (en) BICYCLE INHIBITORS OF NOTUM PECTINACETILESTERASE AND A PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND